Proper Joint Care Cardiovascular health Immunity Allergy

HOME > Research


Proper Joint Care

Human Clinical Study Ⅰ(17):
Zenk et al. (2002) divided 42 subjects randomly into three groups including a S100 Milk Protein Concentrate (MPC) group (4g daily), a glucosamine sulfate group (1.5g daily) and a placebo control group for a six week clinical study(17). The Western Ontario and McMaster Universities Arthritis Index (WOMAC)(21) was the major functional assessment tool. Assessment was carried out at the beginning of the study and in the second, fourth and sixth weeks. Vital signs (e.g. blood pressure, pulse and body temperature), weight and adverse reactions were also assessed. Blood tests were carried out at the beginning of study and in the sixth week, in order to monitor differential blood counts and blood chemistry.


Fig. 4. In the WOMAC assessment showing the treatment effects of S100 MPC on osteoarthritis symptoms, the S100 MPC group showed significant and persistent improvement versus placebo(17).

Fig. 5. In the assessment using WOMAC for determining the treatment effect size for S100 MPC and glucosamine on osteoarthritis, S100 MPC showed better results than glucosamine(17).


WOMAC results showed that the arthritic symptoms of subjects in the S100 MPC group and glucosamine group were significantly relieved. In addition, the S100 MPC group showed persistent improvement, while the glucosamine group only showed the greatest improvement in the second week (Fig. 4).

Effect size assessment of the study was calculated by the formula(22) of Hedges and Cohen. Results of the study showed that the scores of the S100 MPC group were higher than that of glucosamine for every individual item scored (effect sizes of both were greater than 0.8), and in WOMAC scores, 60% of the scores for the S100 MPC group were higher than those of the glucosamine group (Fig. 5). The WOMAC treatment effect size scores for all items were more than 1.3 for the S100 MPC group, which showed that the ability to relieve arthritic symptoms was far superior to glucosamine.


Human Clinical Study Ⅱ(18):

Fig. 6. KOOS and WOMAC assessment results showed significant improvement for the S100 MPC group(18).

Colker et al. (2002) divided 31 subjects randomly into an ordinary drink group (control group) and a S100 MPC drink group (treatment group) for a six weeks study in which 12 ounces of each beverage was consumed daily. WOMAC and the Knee Osteoarthritis Outcome Score(23) (KOOS) were major functional assessment tools. Other items such as vital signs, weight, blood analysis and adverse reactions were also assessed.

KOOS and WOMAC results both showed that S100 MPC significantly improved indexes of pain, knee joint discomfort, daily activities and total WOMAC scores (Fig. 6).


Immune today, healthy everyday.

These statements have not been evaluated by the Food and Drug Administration.

The products mentioned here are not intended to diagnose, treat, cure or prevent any disease.